A Phase I-II Study of Treatment of Metastatic Melanoma Using Induction Therapy With Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab (BBI)

Trial Profile

A Phase I-II Study of Treatment of Metastatic Melanoma Using Induction Therapy With Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab (BBI)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 Aug 2013

At a glance

  • Drugs Bevacizumab (Primary) ; Aldesleukin; Cisplatin; Interferon alpha-2b; Ipilimumab; Temozolomide; Vinblastine
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 May 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top